Home > Insider Trading > Filing (0001479290-19-000038)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1479290	Revance Therapeutics Inc.	RVNC	Pharmaceutical Preparations (2834)	770551645

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1597583	Daniel L Browne	C/O Revance Therapeutics, Inc. 7555 Gateway Boulevard Newark CA 94560	Ceo And President	Yes	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Disposition	2019-03-15	3,256	$15.45	165,687	No	4	F	Direct
Common Stock	Disposition	2019-03-15	2,881	$15.45	162,806	No	4	F	Direct
Common Stock	Disposition	2019-03-18	11,613	$15.51	151,193	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	F	Direct
No	4	F	Direct
No	4	S	Direct

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	409	Indirect	See footnote

Footnotes

Represents the number of shares withheld by and surrendered to the issuer on March 15, 2019, to satisfy tax withholding obligations that arose in connection with the vesting of a Restricted Stock Award ("RSA") for 28,250 shares. The RSA vests in three equal annual installments from March 15, 2018, subject to Mr. Browne's Continuous Service (as defined in the Issuer's 2014 Equity Incentive Plan) on each vesting date.
Represents the number of shares withheld by and surrendered to the issuer on March 15, 2019, to satisfy tax withholding obligations that arose in connection with the vesting of an RSA for 25,000 shares. The RSA vests in three equal annual installments from March 15, 2016, subject to Mr. Browne's Continuous Service (as defined in the Issuer's 2014 Equity Incentive Plan) on each vesting date.
The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by Mr. Browne.
The price reported in Table 1, Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $15.19 to $15.74. Mr. Browne undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range.
These shares are held by the Dan and Brenda Browne Living Trust. Mr. Browne is a Trustee of the Dan and Brenda Browne Living Trust.